Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

New drugs could help fight antibiotic resistance
Image pills
Current antibiotics work by killing bacteria, or stopping it from growing.
AV drugs stop bacteria from harming the host

Scientists say a new type of drug could help fight antibiotic resistance, by stopping bacteria from harming the host.

Current antibiotics aim to kill bacteria, or stop them growing, but scientists from the University of Edinburgh say this dramatically alters how the bugs evolve and helps resistant strains to survive.

After conducting a five-year review of research in the field, scientists believe anti-virulence (AV) drugs could stop the growing resistance to antibiotics.

AV drugs work by stopping the harmful part of the bacteria from functioning - without directly harming or killing the bugs. In this way, the treat the infection without promoting drug resistance.

Experts warn that as antibiotic resistance grows, curable infections could become life-threatening if the bacteria responsible becomes immune to current treatments.

According to the team from Edinburgh, recent research suggests AV drugs could provide an effective and longer lasting alternative to existing treatments.

Findings indicate the new drugs could work well alone, or combined with existing drugs.

"Our findings reveal that there are opportunities to make real progress in the fight against antibiotic resistance," said researcher Richard Allen.

"Gaining a greater understanding of how virulence affects bacterial growth in the host should aid us in our efforts to develop effective AV drugs."

The study has been published in the journal Nature Reviews Microbiology.

Become a member or log in to add this story to your CPD history

Greyhound Board announces change to vaccination guidance

News Story 1
 The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.

The change comes in response to the reduced availability of the 'L2' Leptospirosis vaccine across the UK, and aims to support best biosecurity practice across the racing greyhound population.

GBGB veterinary director Simon Gower, said "While rare, Leptospirosis is a serious infectious disease that can affect both dogs and humans, so it is vital that we offer our greyhounds the broadest possible protection.  

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.